Navigation Links
Modifying an anti-cancer drug makes it more specific
Date:12/3/2007

Imatinib (marketed as Gleevec in the US and Glivec in Europe and Australia) is used to treat various cancers, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). It can be used to treat these two distinct types of cancer because they are caused by related proteins tyrosine kinases. However, this lack of specificity for a single protein means that imatinib can also inhibit tyrosine kinases that mediate normal bodily functions and it has been reported that in some patients this causes a toxic effect on the heart. To address some of these problems, Ariel Fernndez and colleagues at Rice University, Houston, have engineered a modified form of imatinib (known as WBZ_4) that inhibited the tyrosine kinase behind GISTs (c-KIT) as effectively as imatinib did, and that neither inhibited the tyrosine kinase behind CML (BCR-Abl) nor had toxic effects on the heart when it was administered to mice. Importantly, WBZ_4 was as effective as imatinib at reducing tumor volume and weight in a mouse model of GISTs. As noted by George Demetri from the Dana-Farber Cancer Institute, Boston, in the accompanying commentary, this study gives hope that in the future it might be possible to construct ever-better agents that can be combined safely and effectively to manage, and eventually cure, many forms of human cancer.


'/>"/>

Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related biology technology :

1. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
2. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Web Portal Makes Organ Donation Easy
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
7. Argonne researcher studies what makes quantum dots blink
8. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
9. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
10. BioSpecifics to Present at the 9th Annual Healthcare Conference of Acumen Bio Fin Rodman Renshaw LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Raleigh, NC (PRWEB) January 15, 2014 ... enhancement to its Online Web Portal for Life Science organizations ... ability to specify the subject matter of their documents in ... This will help reduce time-to-delivery of translations, often a critical ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 Date: ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, ... only national nonprofit organization solely dedicated to finding a cure ... those affected worldwide, will host its annual Crystal Ball on ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a ... innovative therapies addressing major unmet medical needs using ... Notice of Allowance from the United States Patent ... compounds (sd-rxRNA®), for the treatment of fibrosis. The ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... the promotions of Linda Arterburn, PhD, Francisco Leon, MD, ... "We are pleased,to announce the promotions of several of ... a fine group of talented people working here to ... with celiac,disease, asthma, eye disorders, and other areas to ...
... Business Update to Investors, WILMINGTON, Del., Oct. ... Vice President & General Manager John Ranieri,said the ... programs to,market are on track and making significant ... conversion of cellulosic feedstocks,economically into biofuels., "Biobutanol ...
... OF PHASE II DATA FOR LEAD DRUG CANDIDATE ... Oct. 2 Transave, Inc., a,biopharmaceutical company focused ... of serious lung diseases,today announced that it has ... and Compass Horizon Funding Company LLC, an affiliate ...
Cached Biology Technology:Alba Therapeutics Corporation Announces Promotions 2Alba Therapeutics Corporation Announces Promotions 3Alba Therapeutics Corporation Announces Promotions 4DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 2DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 3Transave, Inc. Secures $12.5 Million in New Financing 2Transave, Inc. Secures $12.5 Million in New Financing 3Transave, Inc. Secures $12.5 Million in New Financing 4Transave, Inc. Secures $12.5 Million in New Financing 5
(Date:4/24/2014)... and the University of North Carolina at Chapel Hill ... identify arterial plaque that is at high risk of ... At issue is the plaque that builds up in ... deemed "vulnerable," meaning that they are more likely to ... or stroke. , "Existing state-of-the-art technologies are capable of ...
(Date:4/24/2014)... turtle is the largest river turtle in North America, ... almost a century. Now researchers from Florida and the ... one species but three. , Examining museum specimens ... in this ancient reptile. , Once heavily hunted for ... of Campbell,s Turtle Soup in the 1960s the ...
(Date:4/23/2014)... data shows Africa,s Congo rainforest, the second-largest tropical rainforest ... greenness over the past decade. , The study, led ... of New York, shows between 2000 and 2012 the ... intensified. The research, published Wednesday in Nature , ... explore the effects of long-term drought on the Congo ...
Breaking Biology News(10 mins):New ultrasound device may add in detecting risk for heart attack, stroke 2Two new US turtle species described 2Two new US turtle species described 3NASA satellites show drought may take toll on Congo rainforest 2NASA satellites show drought may take toll on Congo rainforest 3
... The age at which a person takes a first ... drinkers the most susceptible to severe problems. A team ... Medicine in St. Louis, studied 6,257 adult twins from Australia. ... an early age are more likely to develop a more ...
... subsidies to fossil fuels are attributed to tax breaks ... be released on Friday by the Environmental Law Institute ... for Scholars. The study, which reviewed fossil fuel ... the lion,s share of energy subsidies supported energy sources ...
... Hopkins School of Medicine have discovered how one antioxidant ... the development of spinal cord neurons. The research, publishing ... known mechanism of protein control. "This is the ... control neuronal differentiation," says Shanthini Sockanathan, Ph.D., an associate ...
Cached Biology News:Young age at first drink may affect genes and risk for alcoholism 2Young age at first drink may affect genes and risk for alcoholism 3US tax breaks subsidize foreign oil production 2Antioxidant controls spinal cord development 2
... The transformation of Saccharomyces cerevisiae, as ... routine procedure in many molecular biology laboratories. ... high efficiencies with plasmid and linear DNAs ... has made routine plasmid transformations and library ...
...
... jetSI-ENDO-FluoF is a ... nm; emission at 520 nm), ... These reagents are used to ... investigate the intracellular delivery and ...
... R&D Systems Cell and Tissue Staining Kits ... a broad range of histological and cytological ... primary IgG antibodies manufactured by either R&D ... is based on the formation of the ...
Biology Products: